TAURUS

Principal Investigator: Hassan Yaish
Keywords: Hemophilia A , Kovaltry , Prophylaxis Department: Pediatric Administration
IRB Number: 00102667 Co Investigator:  
Specialty: Pediatrics, General
Sub Specialties:
Recruitment Status: Recruiting

Contact Information

Rebbecca Hanshew
rebbecca.perez@hsc.utah.edu
801-587-7514

Brief Summary

The primary objective of this study is to investigate weekly prophylaxis dosing regimens used in standard clinical practice.

In addition the study will capture reported bleed rate, pattern of change in KOVALTRY prophylaxis dose & dosing frequency, reason for choice of treatment regimen, FVIII product switch pattern, patient treatment satisfaction and adherence, KOVALTRY pharmacokinetic data (if performed), KOVALTRY consumption, as well as safety data.

Inclusion Criteria

Male patients diagnosed with moderate to severe hemophilia A (≤ 5% FVIII:C)

Any age

≥ 50 exposure days (EDs) to any FVIII product

Patients with no history of inhibitors

Currently on (started within 3 months of study enrollment) or plan to start prophylaxis therapy with KOVALTRY

Written informed consent

Exclusion Criteria

Patients participating in an investigational program with interventions outside of routine clinical practice

Patients with an additional diagnosis of any bleeding/coagulation disorder other than hemophilia A